Drug May Lead to 6% Weight-loss in Type-2 Diabetics
A clinical trial in Denmark has shed light on the fact that drug liraglutide can lead to weight loss in overweight or obese people with type-2 diabetes.
One of the authors at Novo Nordisk said after conclusion of the second phase, the drug can achieve 6% weight loss in overweight people. Company officials mentioned that second phase 3a trial is a part of the clinical development program for liraglutide 3 milligram as an obesity treatment.
Through the experiment almost 846 overweight or obese people with type 2 diabetes were followed. They were treated with liraglutide 3 mg, liraglutide 1.8 mg or placebo.
After a period of 56 weeks, the experiment ended and the subjects were tracked for a 12-week observational period.
For some subjects it was witnessed that the ones with a weight of approximately 233 pounds and a body mass index of 37, had a weight loss of 6%. The trial was followed by 12-week program to authenticate the results.
Mads Krogsgaard Thomsen, executive vice-president and chief science officer of Novo Nordisk, said, "This trial showed it was possible to achieve both clinically significant weight loss and excellent glucose control with a single treatment in patients with type 2 diabetes".